Model 1# | Model 2$ | |||||||
---|---|---|---|---|---|---|---|---|
Variable | B | β | p | B | 95% CI | β | p | |
Global QoL [constant] | 82.509 | [76.76, 88.26] | ||||||
Number of symptoms | -1.201 | − 0.389 | < 0.001 | − 0.171 | [-0.675, 0.333] | − 0.055 | 0.503 | |
Physical symptoms | -27.634 | − 0.617 | < 0.001 | -24.363 | [-32.172, -16.555] | − 0.544 | < 0.001 | |
Psychological symptoms | -12.467 | − 0.341 | < 0.001 | − 0.688 | [-6.656, 5.279] | 0.019 | 0.820 | |
Age (years) | 0.200 | 0.065 | 0.443 | |||||
Highest educational level (elementary school/high school) | − 0.606 | − 0.012 | 0.895 | |||||
Highest educational level (elementary school/ university) | -4.917 | − 0.100 | 0.275 | |||||
Time since metastatic disease (in months) | 0.040 | 0.042 | 0.622 | |||||
PSA (ng/ml) | − 0.021 | − 0.209 | 0.012 | − 0.015 | [-0.028, − 0.001 | − 0.143 | 0.033 | |
Analgesic use | -9.902 | − 0.223 | 0.007 | -6.767 | [-12.486, -1.048] | − 0.153 | 0.021 |